Here’s How Biotech Changes Lives

As early as age 9, Allison felt like a “big toxic load”…

She didn’t know exactly what was wrong. But she was in a lot of pain. And she didn’t have any friends.

Still, Allison tried to live a productive life. She worked as an actor, a writer, and a radio DJ.

But then, a late-night manic episode interrupted one of Allison’s radio gigs. And after a trip to the hospital, doctors diagnosed her with bipolar disorder.

Allison managed her condition for a decade or so before things got worse. After another hospital visit, she received antipsychotic medication for the first time.

Once again, her condition was manageable.

But years later, Allison’s legs started to involuntarily kick. And her torso would randomly twist.

Allison went to see a local doctor, who was less than sympathetic. As she later recalled, he said…

Young lady, you’re going to need to suck it up. This isn’t going to get any better for you.

Allison tried to just “suck it up.” But before long, she developed even more problems…

Her mouth would clench and move on its own. Her eyes started to blink rapidly. And her shoulders, chest, and neck started to move by themselves.

Folks in Allison’s inner circle always understood what was happening. But when any of these involuntary movements occurred in public, strangers would glare and gawk at her.

In short, Allison was suffering from a disorder called tardive dyskinesia (“TD”).

TD is associated with drugs used to treat various forms of psychosis. These drugs aim to block dopamine – a chemical messenger that works between the brain and the rest of the body. But like any medication, side effects can happen.

So in other words… Allison’s bipolar-disorder medication was causing her TD.

Allison could’ve gotten relief from the TD symptoms if she just stopped using the medication. But that would’ve brought back the psychotic behaviors.

So Allison knew that wasn’t the answer.

Fortunately for Allison, everything changed for the better in May 2017. That’s when a new, highly effective treatment for TD became available…

Allison’s quest to learn more about TD led her to discover this treatment. And after using it for just a couple of weeks, her body’s uncontrollable movements subsided.

Allison still suffers from TD today. But it doesn’t dominate her life like before.

Folks, this is the power of biotechnology. And it follows the latest recommendation I made in the space to paid subscribers of our Power Gauge Investor newsletter.

Now, I can’t give you all the details of that recommendation. It wouldn’t be fair to paying subscribers. But still, you need to be aware of a major change taking place in this space…

The SPDR S&P Biotech Fund’s (XBI) rating in the Power Gauge flipped to “bullish” at the end of December. And XBI triggered a relative strength “buy” signal in our system last week.

This means that the biotech space, as measured by XBI, has been outperforming the broad market recently. Over the past three months, XBI has soared about 29%. Meanwhile, the S&P 500 Index has climbed roughly 15% over that same time frame.

Combined with the recent “buy” signal based on our proprietary measure of relative strength, this all points to more upside ahead.

So, if you’re not paying attention to biotech stocks today… I recommend you look into them.

Good investing,

Marc Chaikin

P.S. As I mentioned, our latest recommendation in Power Gauge Investor is in the biotech space. It’s the company behind Allison’s life-changing treatment…

This company isn’t like most biotech firms. It’s already profitable and financially strong. Furthermore, Wall Street doesn’t fully realize how much potential growth lies ahead. And beyond that, many investors don’t appreciate the value of the rest of the company’s pipeline.

Even better, the Power Gauge is “very bullish” on this stock today. If you aren’t already a Power Gauge Investor subscriber, find out how to gain immediate access to this recommendation by clicking here.

Scroll to Top